BG
CORT icon

BlackRock Group’s Corcept Therapeutics CORT Stock Holding History

BlackRock Group’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$308K Buy
42,349
+19,776
+88% +$155K ﹤0.01% 2526
2016
Q3 		$147K Buy
22,573
+1,089
+5% +$6.33K ﹤0.01% 2725
2016
Q2 		$117K Sell
21,484
-364
-2% -$1.89K ﹤0.01% 2743
2016
Q1 		$103K Buy
21,848
+8,265
+61% +$32.2K ﹤0.01% 2756
2015
Q4 		$67K Sell
13,583
-485
-3% -$2.19K ﹤0.01% 2774
2015
Q3 		$53K Buy
14,068
+2,854
+25% +$14.5K ﹤0.01% 2840
2015
Q2 		$67K Buy
+11,214
New +$68.7K ﹤0.01% 2835
2013
Q4 		– Sell
-2,397
Closed -$4K – 2688
2013
Q3 		$4K Hold
2,397
– – ﹤0.01% 2876
2013
Q2 		$4K Buy
+2,397
New +$4.31K ﹤0.01% 2599

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Group's CORT Position: Q4 2016 in Review

BlackRock Group increased its Corcept Therapeutics (CORT) stake by 88% in Q4 2016, buying an estimated $155K and bringing the position to 42,349 shares worth $308K. The position accounts for ﹤0.01% of the portfolio, ranked #2526.

BlackRock Group first reported a position in CORT in Q2 2013 and has held it in 9 quarters since. 135 funds tracked by Wall St. Rank hold CORT as of Q4 2016.

  • BlackRock Group held 42,349 shares of Corcept Therapeutics worth $308K as of Q4 2016.
  • BlackRock Group bought 19,776 Corcept Therapeutics shares in Q4 2016, an estimated $155K.
  • Corcept Therapeutics made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2526 holding.
  • BlackRock Group first reported a position in Corcept Therapeutics in Q2 2013 and has held it in 9 quarters since.
  • 135 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.